BRAF NP_004324.2:p.V600E

Who we are

  • April 5, 2022
    Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer